论文部分内容阅读
目的测定血清ＥＣＰ并探讨其在哮喘患者中的临床应用价值。方法使用ＵｎｉＣＡＰ１００型自动酶免疫荧光分析系 统测定。结果测定５０例正常人，４７例缓解期哮喘患者和４２例发作期哮喘患者血清ＥＣＰ平均水平分别为７．４２±３．５６，１４．７５± ４．８２和３５．８０±４．５５μｇ／Ｌ（ｘ±ｓ），各组间均有明显差异，以发作期患者组ＥＣＰ升高最为显著（ｐ＜０．０１）。上述４２例发作期哮喘 患者经抗炎治疗后，ＥＣＰ平均水平为２４．６６±５．１２μｇ／Ｌ，较治疗前明显下降（Ｐ＜０．０１）。结论血清ＥＣＰ水平反映气道的炎症 程度，可作为哮喘的诊断、疗效监测和预后判断指标。
Objective To determine serum ECP and explore its clinical value in patients with asthma. Methods UniCAP100 automatic enzyme immunofluorescence assay system. Results The mean serum ECP levels in 50 normal subjects, 47 remission asthma patients and 42 seizure asthma patients were 7.42 ± 3.56, 14.75 ± 4.82 and 35.80 ± 4.55 μg / L (x ± s). There was a significant difference between the groups, and the most significant increase of ECP was seen in the patients of the attack period (p <0.01). After the anti-inflammatory treatment, the average level of ECP was 42.66 ± 5.12μg / L in 42 cases of asthma exacerbation patients, which was significantly lower than that before treatment (P <0.01). Conclusion Serum ECP level reflects the degree of airway inflammation and can be used as an indicator of asthma diagnosis, efficacy monitoring and prognosis.